Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILLUMINATE-2: Subcutaneous LY2127399 in Systemic Lupus Erythematosus
2010-022100-42Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tabalumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: SLE Responder Index-5 response at week 52. Started Jan 2011; status: terminated.
02
Drugs
tabalumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2010-022100-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022100-42.